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Heart failure remains a leading cause of morbidity and
mortality, with increasing numbers of patients being affected
annually. Developing models and approaches for predicting
adverse outcomes and survival is of particular importance in
determining when to initiate speciﬁc therapies, in particular
those for advanced heart failure such as cardiac transplantation
and mechanical circulatory support. The ﬁrst approach was
the New York Heart Association functional classiﬁcation,
which provided the ability to risk stratify patients by using the
subjective assessment of exercise tolerance (1). To some
degree, this classiﬁcation has stood the test of time because it is
still used to determine when to initiate therapies such as
deﬁbrillator implantation or cardiac resynchronization, but it
is limited by its subjectivity. Efforts to improve prognostica-
tion in patients with heart failure include peak oxygen
consumption during cardiopulmonary exercise testing in
ambulatory heart failure patients (2). This parameter became
an important way of identifying patients whose survival would
be improved with cardiac transplantation.See page 2253As therapies for heart failure became more sophisticated,
efforts were made to develop more sophisticated scoring
models that would include a variety of clinical and laboratory
parameters. One such model is the Heart Failure Survival
Score (HFSS), which has 7 variables (3). The Seattle Heart
Failure Model (SHFM) incorporates 24 variables, including
clinical ﬁndings, laboratory parameters, and speciﬁc medical
and device therapy (4). For both scoring models, patients can
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contents of this paper to disclose.scores derived from these variables. SHFM is limited in that
it may overestimate prognosis in patients with advanced heart
failure, potentially failing to identify patients who would
beneﬁt from advanced therapies. The models seem to be
most successful when combined for predicting adverse events
in the medium-risk group. This group is probably the most
critical for obtaining reliable prognosticators because the
other groups have relatively few (low risk) or have frequent
and signiﬁcant (high risk) adverse events. It is prediction of
outcomes in the medium-risk group that has been most
difﬁcult and problematic clinically, and the combination of
the HFSS and the SHFM has provided some guidance; any
additional information that could provide more robust
predictive capabilities would be very important clinically.
Heart failure results from effects on the cardiovascular
system of neurohormonal perturbations and also has
systemic effects as a result of hemodynamic derangements
such as congestion and diminished cardiac output. One
consequence is hyponatremia as a result of activation of the
renin-angiotensin and vasopressin systems. Hyponatremia
has been identiﬁed as a predictor of poor outcome in
hospitalized patients with heart failure (5–8). Serum sodium
has been incorporated in both the HFSS and SHFM as part
of the prediction algorithms.
Among the systemic effects of heart failure is hepatic
congestion and subsequent abnormalities of hepatic func-
tion. These abnormalities identify a heart failure patient
population at risk for worse outcomes, particularly death.
Hepatologists have developed their own scoring system for
hepatic function, the Model for End-Stage Liver Disease
(MELD) in patients with end-stage liver disease being
considered for liver transplantation; the goal is to determine
their prognosis before transplantation and to prioritize
listing for transplant based on this prognosis (9,10). The
MELD uses 3 noncardiac biomarkers that reﬂect the
severity of hepatic dysfunction on synthesis (international
normalized ratio [INR]), metabolism (total bilirubin), and
renal function (creatinine). MELD has been applied as
a prognosticator for cirrhotic patients sent for cardiac surgery
and to determine the prognosis of patients with stage
D heart failure who are referred for mechanical circulatory
support or heart transplantation (11–14).
In this issue of the Journal, Kim et al. (15) retrospectively
studied 343 patients with ambulatory advanced heart failure
undergoing evaluation for cardiac transplantation, 260 of
whom had complete datasets. These datasets included
clinical parameters, medication and device therapy infor-
mation, and laboratory values as well as hemodynamic
measures. The authors applied the MELD as well as 2 of its
modiﬁcations, the MELDNa (which includes serum sodium
levels) and the MELD-XI (which does not include INR and
thus can be applied to heart failure patients with elevated
INRs due to therapeutic anticoagulation with warfarin) (16).
The various MELD scores were used separately and in
combination with the HFSS and SHFM in this study.
MELD scores alone were able to identify patients’ risk for
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2263the endpoint of death, heart transplantation, or ventricular
assist device implantation. When MELD scores were
combined with the HFSS and SHFM, low (<12) MELD
scores were found to predict good outcomes and clinical
stability in the low-risk group whereas high (>12) scores in
the medium-risk group identiﬁed patients at higher risk for
the aforementioned outcomes. MELD scores were inde-
pendent of peak oxygen consumption and some of the other
parameters in HFSS and SHFM. MELDNa scores also
provided robust discrimination of patients into high and low
risks for the outcome endpoints. The use of MELD-XI was
potentially attractive because it might provide additional
prognostic information in patients who received anti-
coagulation therapy with warfarin because this scoring system
does not include the INR (16). Only this MELD scoring
system was able to identify patients with diminished survival
in anticoagulated patients, but the survival difference was
more pronounced and hence the discrimination more robust
for nonanticoagulated patients; the MELD and MELDNa
scoring systems were of no use for anticoagulated patients.
The authors (15) are to be commended on applying what
is a simply calculated scoring system using readily available
laboratory data to an overlooked population with signiﬁcant
hepatic dysfunction, those with advanced heart failure. The
question is what steps should be taken next to explore the
utility of the MELD and how should cardiologists apply this
information clinically. Certainly, calculation of the MELD
and MELDNa scores is simple and, as was shown in the
current study, can be done longitudinally to assess disease
progression. The utility of MELD scoring in heart failure
outcomes prognostication would be strengthened with
a prospective study encompassing patients with a variety of
severities of heart failure and with MELD scoring to assess
response to initiation and/or optimization of heart failure
medical therapies and devices as well as prognosis and rela-
tionship to clinical outcomes. It is not known at present, for
example, whether optimization of medical therapy can lower
the MELD scores. In addition, the utility of MELD-XI is
apparently more limited because it seems to be only modestly
predictive for patients receiving warfarin anticoagulation; the
other 2 MELD scoring systems cannot be used in these
patients because the INR is part of the score. This is not
a trivial issue given the frequent coincident occurrence of
heart failure and atrial ﬁbrillation and the necessity of anti-
coagulation therapy in these patients. This situation may be
mitigated in the future as newer antithrombotic agents such
as dabigatran and rivaroxaban are used more frequently in
patients with atrial ﬁbrillation, resulting in less perturbations
of INR. The utility of MELD scores in patients with heart
failure who are receiving these agents is unknown. The utility
of MELD scores speciﬁcally for predicting sudden cardiac
death and arrhythmic events was not deﬁned.
In summary, the addition of the MELD and MELDNa
scores to the traditional heart failure outcome prediction
models may provide additional data regarding risk that is
independent of the traditional models such as HFSS andSHFM. Although the MELD is simple to use and its utility
may be enhanced with MELDNa, prospective studies are
needed to deﬁne its utility in a broad range of heart failure
patients as well as its utility in monitoring changes in medical
anddevice therapy.The applicationofMELDismoredifﬁcult
in patients receiving anticoagulation therapy with warfarin.
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